Skip to main content
OpenTrials
Completed

NCT Number: NCT02712892

I-CAN Biocollection

Intracranial aneurysm (IA) is an asymptomatic cerebrovascular abnormality affecting 3.2% of the general population. The devastating complication of IA is its rupture, resulting in subarachnoid haemorrhage that can lead to severe disability and death. Unfortunately, there are neither reliable clues nor diagnostic tools to predict the formation and/or the fate of an IA in a given individual. Also, there is no pharmacological drug available to prevent the rupture of aneurysm and subsequent subarachnoid haemorrhage. Current treatments are invasive with a significant risk of procedural morbidity. Thus, still now, the management of patients with IA remains extremely challenging and still controversial. Although the pathogenesis of IA has been the subject of many studies for the last decade, the mechanisms underlying IA formation, growth and rupture are still mostly unknown and relevant animal models of IA are not available. Familial history of IA predisposes to IA formation and rupture and increasing evidence suggest a genetic component of IA formation, with heterogeneous modes of inheritance and penetrance. This project, gathering neuroradiologists, geneticists and vascular biologists, addresses the urgent need to understand the pathogenic mechanisms of IA to develop diagnostic and predictive tools of risk of IA. The investigators propose to identify IA-causing variants by whole-exome sequencing in familial forms of the disease. The investigators hypothesises that the functional analysis of the causal/susceptibility variants thus identified will provide clues to understanding the pathological mechanisms of IA formation, and the bases for developing diagnostic tools. This project aims at meeting this challenge. Based on preliminary data that already allowed to identify such a variant, and the combination of genetic and functional investigations, the specific objectives of this project are: - To identify IA-causing variants in familial forms of the disease by whole-exome sequencing; - To understand the function of these genes/variants in the formation and rupture of IA by molecular and cellular approaches and generation of relevant animal models; - To discover potential biomarkers of risk of IA formation and/or rupture.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Angers University Hospital, Angers, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

indexes and related cases (familial) of intracranial aneurysms:

  • Index: Any patient consulting for a major IA and some typical bifurcation with at least one other case reached akin IA 1st degree
  • Related: All similar to the first degree, aged 20 or more, patients with a family background of IA and some typical bifurcation (≥2 achieved) For the latter, directed by screening with Magnetic resonance imaging (MRI) sequence Time of Flight (TOF), axial T2, EGT2.
  • biocollection of Written Consent for participation in the collection of biological samples

Inclusion criteria

sporadic cases of IA:

  • Any patient consulting for IA and some typical bifurcation
  • Patients aged 20 years or older
  • biocollection of Written Consent for participation in the collection of biological samples

Non Inclusion Criteria:

  • Patients who have shown the inability or refusal to sign the consent informed biocollection
  • syndromic diagnosis known as AIC provider
  • Marfan Syndrome
  • AOS with SMAD 3
  • Danlos Syndrome Elhers type II and IV
  • Autosomal Dominant Polycystic
  • Moyamoya Syndrome
  • character of IA:
  • Dissecting or fusiform
  • Combined with an arteriovenous malformation
  • Blister-like
  • mycotic
  • Pathology of the cerebral white matter detected on MRI suggestive:
  • Mutation COL4A1

Treatment and study plan

Non Interventional Study

Genetic

Primary outcomes

  1. Presence or absence of genetic abnormalitie

    Time frame: Until one year

    Identification of genetic abnormalities segregant with the presence of intracranial aneurysms in the informative families recruited. Sequencing of the whole exome in a cohort of patients carriers of familial forms of intracranial aneurysms.

    Analysis of blood level of the GAIA 1 protein in a large cohort of familial and sporadic carriers of intracranial aneurysms

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

Registry information

Official study title

IntraCranial ANeurysms: From Familial Forms to Pathophysiological Mechanisms

Acronym: I-CAN

Important dates

Study start
2016
Primary completion
2019
Study completion
2020
First posted
Mar 18, 2016
Registry last updated
Sep 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.